(Q44920861)

English

The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

0 references

Streptococcus pneumoniae

1 reference

based on heuristic

inferred from title

antimicrobial resistance

1 reference

based on heuristic

inferred from title

Angela B Brueggemann

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Michael A. Pfaller

2

object named as

Pfaller MA

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Meridith E. Erwin

3

object named as

Erwin ME

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

author name string

Doern GV

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Jones RN

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

publication date

1 December 1998

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Diagnostic Microbiology and Infectious Disease

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

313-316

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900081-9

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900081-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900081-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900081-9

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900081-9

7 January 2021

based on heuristic

inferred from DOI database lookup

North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900081-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900081-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900081-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900081-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Franklin County Pneumonia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900081-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900081-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2898%2900081-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0732-8893(98)00081-9

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44920861&oldid=2057038810"